Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer (Q827694)
From MaRDI portal
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer |
scientific article |
Statements
Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer (English)
0 references
13 January 2021
0 references
adoptive T cell transfer
0 references
TCR T cells
0 references
IL-2 treatment
0 references
combination cancer therapy
0 references
mathematical oncology
0 references
0 references
0 references
0 references
0 references
0 references
0 references
